mortality/aging
• mice die 10 to 13 days after tamoxifen treatment
|
immune system
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• defects in secondary lymphoid organs in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
digestive/alimentary system
• 7 to 9 days after tamoxifen treatment
|
cellular
• tamoxifen-treated mice exhibit impaired biogenesis of large ribosomal subunit in hematopoietic stem cell and multipotent progenitor compared with control mice
|
hematopoietic system
N |
• hematopoietic stem cell mobilization occurs normally in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• tamoxifen-treated mice exhibit cell autonomous defects in hematopoiesis
|
• in tamoxifen-treated mice
• tamoxifen-treated mice exhibit impaired biogenesis of large ribosomal subunit in hematopoietic stem cell and multipotent progenitor compared with control mice
|
• in tamoxifen-treated mice
|
• severe in tamoxifen-treated mice
|
• decreased in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• reduced hematopoietic stem cell and multipotent progenitor quiescence in tamoxifen-treated mice
|
endocrine/exocrine glands
• in tamoxifen-treated mice
|